ArticleProceedings of the National Academy of Sciences of the United States of America2016
Detection, phenotyping, and quantification of antigen-specific T cells using a peptide-MHC dodecamer.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 95 citations in OpenAlex.
- T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells.Nature protocols · 2026Review
- The challenge and promise of studying human antigen-specific T cells.Nature reviews. Immunology · 2026Review
- Peptide-driven identification of TCRs reveals dynamics and phenotypes of CD4 T cells in tuberculosis.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Identification of antigen-specific functional CD8iScience · 2025Article
- AI/ML-empowered approaches for predicting T Cell-mediated immunity and beyond.Frontiers in immunology · 2025Article
- Low-affinity CD8American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2024Article
- The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells.Molecular cancer · 2023Review
- What's the Catch? The Significance of Catch Bonds in T Cell Activation.Journal of immunology (Baltimore, Md. : 1950) · 2023Review
- Antigen-specific and cross-reactive T cells in protection and disease.Immunological reviews · 2023Review
- CD4Nature immunology · 2023Review
- Genetically engineered CD80-pMHC-harboring extracellular vesicles for antigen-specific CD4Frontiers in bioengineering and biotechnology · 2023Article
- MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection.Frontiers in immunology · 2023Article
- Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy.Frontiers in immunology · 2023Review
- Inflammatory Cytokines That Enhance Antigen Responsiveness of Naïve CD8International journal of molecular sciences · 2022Article
- Nanoscale organization of two-dimensional multimeric pMHC reagents with DNA origami for CD8Nature communications · 2022Article
- The transcription factor RFX5 coordinates antigen-presenting function and resistance to nutrient stress in synovial macrophages.Nature metabolism · 2022Article
- Article
- Enriching and Characterizing T Cell Repertoires from 3' Barcoded Single-Cell Whole Transcriptome Amplification Products.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.Frontiers in oncology · 2022Review
- Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents.Matter · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Here we report a peptide-MHC (pMHC) dodecamer as a "next generation" technology that is a significantly more sensitive and versatile alternative to pMHC tetramers for the detection, isolation, and phenotypic analysis of antigen-specific T cells. In particular, dodecamers are able to detect two- to fivefold more antigen-specific T cells in both human and murine CD4(+)and CD8(+)αβ T-cell compartments compared with the equivalent tetramers. The low-affinity, tetramer-negative, dodecamer-positive T cells showed comparable effector cytokine responses as those of high-affinity, tetramer-positive T cells. Dodecamers are able to detect early stage CD4(+)CD8(+)double-positive thymocytes on which T-cell receptors are 10- to 30-fold less dense than mature T cells. Dodecamers also show utility in the analysis of γδ T cells and in cytometry by time-of-flight applications. This construct has a simple structure with a central scaffold protein linked to four streptavidin molecules, each having three pMHC ligands or other molecules. The dodecamer is straightforward and inexpensive to produce and is compatible with current tetramer technology and commercially available streptavidin conjugates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.